{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:35:02Z","timestamp":1787826902842,"version":"build-2784847793"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This retrospective study evaluated Bictegravir (BIC)\/emtricitabine (FTC)\/tenofovir alafenamide (TAF) in 24 persons with human immunodeficiency virus type 2 (HIV-2, PWHIV-2), 5 naive and 19 pretreated. After a median follow-up of 37.5 months, all PWHIV-2 had a plasma viral load &amp;lt;40\u2005copies\/mL. Median CD4 count increased significantly from 580 to 625\u2005cells\/mm3, suggesting the effectiveness of BIC\/FTC\/TAF to treat HIV-2 infection.<\/jats:p>","DOI":"10.1093\/cid\/ciae447","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T18:10:56Z","timestamp":1726510256000},"page":"618-620","source":"Crossref","is-referenced-by-count":2,"title":["Immuno-virological and Clinical Follow-up of Persons With HIV-2 (PWHIV-2) Receiving Bictegravir\/Emtricitabine\/Tenofovir Alafenamide Fumarate (BIC\/FTC\/TAF): A Retrospective Study"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-102X","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Joly","sequence":"first","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine M","family":"Ferr\u00e9","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP Laboratoire de Virologie, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9017-4941","authenticated-orcid":false,"given":"Quentin","family":"Le Hingrat","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP Laboratoire de Virologie, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Pharmacologie-Toxicologie, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Cresta","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP Laboratoire de Virologie, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Digumber","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP Laboratoire de Virologie, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2402-643X","authenticated-orcid":false,"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Matheron","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP Laboratoire de Virologie, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Bichat Claude Bernard, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"2025031715495373900_ciae447-B1","doi-asserted-by":"crossref","first-page":"e390","DOI":"10.1016\/S2352-3018(18)30094-8","article-title":"90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2","volume":"5","author":"Gottlieb","year":"2018","journal-title":"Lancet HIV"},{"key":"2025031715495373900_ciae447-B2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/cid\/ciaa275","article-title":"Human immunodeficiency virus-2 (HIV-2): a summary of the present standard of care and treatment options for individuals living with HIV-2 in Western Europe","volume":"72","author":"Berzow","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025031715495373900_ciae447-B3","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1016\/S2352-3018(24)00085-7","article-title":"Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non comparative open-label randomized controlled trial","volume":"11","author":"Eholie","year":"2024","journal-title":"Lancet HIV"},{"key":"2025031715495373900_ciae447-B4","doi-asserted-by":"crossref","first-page":"e00014-9","DOI":"10.1128\/AAC.00014-19","article-title":"Comparison of the antiviral activity of bictegravir against HIV-1 and HIV-2 isolates and integrase inhibitor-resistant HIV-2 mutants","volume":"63","author":"Smith","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025031715495373900_ciae447-B5","doi-asserted-by":"crossref","first-page":"14300","DOI":"10.3390\/ijms232214300","article-title":"High instantaneous inhibitory potential of bictegravir and the new spiro-\u03b2-lactam BSS-730A for HIV-2 isolates from RAL-naive and RAL-failing patients","volume":"23","author":"B\u00e1rtolo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025031715495373900_ciae447-B6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/cid\/ciy324","article-title":"A trial of a single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for the initial treatment of human immunodeficiency virus type 2 infection in a resource-limited setting: 48 week results from Senegal, West Africa","volume":"67","author":"Ba","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025031715495373900_ciae447-B7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/cid\/ciy245","article-title":"First-line raltegravir\/emtricitabine\/tenofovir combination in human immunodeficiency virus type 2 (HIV-2) infection: a phase 2, noncomparative trial (ANRS 159 HIV-2)","volume":"67","author":"Matheron","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025031715495373900_ciae447-B8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/cid\/ciad339","article-title":"Safety and efficacy of triple therapy with dolutegravir plus 2 nucleoside reverse transcriptase inhibitors in treatment-naive human immunodeficiency virus type 2 patients: results from a 48-week phase 2 study","volume":"77","author":"Pacheco","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025031715495373900_ciae447-B9","first-page":"159","volume-title":"EACS Abstracts. HIV Med","author":"Rodrigues","year":"2023"},{"key":"2025031715495373900_ciae447-B10","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1128\/JCM.00724-14","article-title":"New sensitive one-step real-time duplex PCR method for group A and B HIV-2 RNA load","volume":"52","author":"Avettand-Fenoel","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2025031715495373900_ciae447-B11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/jac\/dkx530","article-title":"Minority resistant variants are also present in HIV-2 infected antiretroviral-naive patients","volume":"73","author":"Storto","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025031715495373900_ciae447-B12","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2025031715495373900_ciae447-B13","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1093\/jac\/dkx210","article-title":"CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study","volume":"72","author":"Wittkop","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025031715495373900_ciae447-B14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/COH.0000000000000833","article-title":"Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV","volume":"19","author":"Capeau","year":"2024","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae447\/59385591\/ciae447.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/3\/618\/59385591\/ciae447.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/3\/618\/59385591\/ciae447.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:50:15Z","timestamp":1742226615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/3\/618\/7758762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,16]]},"published-print":{"date-parts":[[2025,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae447","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,15]]},"published":{"date-parts":[[2024,9,16]]}}}